Bacterial Vaginosis Medication: Antibiotics and Alternatives

Bacterial vaginosis is most commonly treated with antibiotics from the nitroimidazole or lincosamide families, specifically metronidazole and clindamycin, which produce initial cure rates around 80 to 85 percent. These medications come in both oral and vaginal formulations, and newer single-dose options have expanded the choices. But the real challenge with BV medication is not getting rid of the infection the first time; it is keeping it from coming back, something that happens in roughly half of treated women within a year.

First-Line Medications and How They Compare

The two workhorses of BV treatment are metronidazole and clindamycin. Metronidazole is available as a 500 mg oral tablet (taken twice daily for seven days) or as a vaginal gel. Clindamycin comes as a vaginal cream or as oral capsules. Head-to-head trials have consistently shown that these options perform similarly. One trial found cure rates of about 84 percent for oral metronidazole, 75 percent for metronidazole vaginal gel, and 86 percent for clindamycin vaginal cream, with no statistically significant differences between them.¹ Another trial reported cure or improvement rates of about 83 percent for clindamycin cream and 78 percent for oral metronidazole, again with no meaningful gap.²

The choice between oral and vaginal formulations usually comes down to side effects and personal preference rather than effectiveness. Oral metronidazole causes nausea in roughly 30 percent of users, abdominal pain in about 32 percent, and a distinctive metallic taste in around 18 percent. Vaginal metronidazole gel cuts those numbers substantially: nausea drops to about 10 percent, abdominal pain to about 17 percent, and metallic taste to about 9 percent.³ The vaginal gel delivers the drug locally, so much less of it reaches the bloodstream.⁴ If you have had bad experiences with oral metronidazole, asking for the vaginal formulation is a reasonable conversation to have with your provider.

One side effect worth knowing about regardless of which antibiotic you take: BV medications can disrupt the vaginal environment enough to trigger a yeast infection. Antibacterial therapy may raise the risk of symptomatic yeast infections in women who are already prone to them.⁵ If you tend to get yeast infections, mention it before starting BV treatment so your provider can plan accordingly.

Single-Dose Treatment With Secnidazole

Taking medication twice a day for a full week is inconvenient, and missed doses make treatment less effective. Secnidazole is a newer antibiotic in the same drug family as metronidazole but with a much longer half-life, meaning a single 2-gram oral dose can do the work of a week-long course. It comes as granules you can sprinkle into food like yogurt or applesauce and swallow without chewing.

In a phase 3 trial, the clinical cure rate for single-dose secnidazole 2 g was about 59 percent versus 25 percent for placebo, and roughly 68 percent of secnidazole-treated patients needed no additional BV treatment at follow-up.⁶ Another randomized trial found clinical cure rates around 68 percent for the 2-gram dose, compared with about 18 percent for placebo.⁷ A systematic review confirmed that the 2-gram dose performs about as well as the standard 7-day course of oral metronidazole.⁸

The cure numbers for secnidazole may look lower than those for metronidazole cited earlier, but that has more to do with how different trials define “cure” and how strictly they measure outcomes than with a real gap in performance. The side-effect profile is mild, with small percentages of women reporting diarrhea, headache, or nausea.⁹ The main drawback is cost: secnidazole is newer and typically more expensive than generic metronidazole, which matters if your insurance coverage is limited.

Why BV Keeps Coming Back

Even with cure rates approaching 80 percent at the 30-day mark, recurrence within 12 months is common.¹⁰ This is one of the most frustrating aspects of BV and the reason research has increasingly shifted from finding better antibiotics to understanding why existing ones fail long-term.

The main culprit is a sticky, protective structure called a biofilm that the bacteria responsible for BV, particularly Gardnerella species, build on the vaginal lining. A biofilm acts like a shield: the bacteria living inside it are far harder for antibiotics to reach and kill than free-floating bacteria are. BV is now understood as a biofilm infection that often resists standard antibiotic treatment.¹¹ Making matters worse, the multiple bacterial species involved in BV appear to help each other survive. Lab research has shown that when three BV-associated species grow together in a biofilm, they tolerate metronidazole better than when each species grows alone, suggesting the community of bacteria itself promotes treatment failure.¹²

Standard antibiotics kill off most of the bacteria, which is why symptoms resolve, but if even a small amount of biofilm survives, it can regrow and re-establish the infection weeks or months later. This is not a case of the bacteria becoming “resistant” in the classic sense you hear about with superbugs; it is the physical structure of the biofilm blocking the drug from doing its job.

The Role of Sexual Partners

For years, clinical guidelines insisted that BV was not sexually transmitted and that treating male partners was unnecessary. That view has been challenged by a landmark Australian trial. In the StepUpRCT study, women whose regular male partners received a combination of oral and topical antibiotics had a BV recurrence rate of 35 percent, compared with 63 percent in women whose partners received no treatment, cutting recurrences by nearly half.¹³ A cost-effectiveness analysis found that this approach would save money overall while improving health outcomes.¹⁴

However, a broader meta-analysis that pooled multiple trials of male partner treatment found no statistically significant reduction in recurrence overall.¹⁵ The discrepancy likely comes down to differences in study design, partner treatment regimens, and populations studied. A separate observational study found that having the same sexual partner before and after treatment was linked to a roughly doubled risk of recurrence, and inconsistent condom use had a similarly elevated risk.¹⁶ The evidence is not yet settled enough for partner treatment to be standard practice everywhere, but if you are in a stable sexual partnership and BV keeps returning, it is a reasonable option to discuss with your clinician.

Non-Antibiotic Options

Given the frustrating cycle of treatment and recurrence, there is understandable interest in alternatives that do not rely on antibiotics. A few have real evidence behind them.

Dequalinium chloride is an antiseptic vaginal tablet that has been used in parts of Europe. A randomized trial comparing it head-to-head with metronidazole found clinical cure rates above 90 percent for both, confirming that dequalinium was noninferior.¹⁷ A systematic review and meta-analysis pooling multiple trials confirmed this finding, with no serious adverse events reported.¹⁸ Since dequalinium is not an antibiotic, it avoids contributing to antibiotic resistance. Availability varies by country, and it is not widely marketed in the United States.

Lactic acid vaginal gel aims to restore the naturally acidic pH of the vagina, which healthy Lactobacillus bacteria maintain. A pilot study found it was inferior to metronidazole for short-term clinical and microbiological cure, but it performed equally well for symptom relief and for preventing BV recurrence over six months.¹⁹ That long-term equivalence is interesting given its gentler side-effect profile, though the evidence is still thin and this remains a pilot-stage finding.

Intravaginal boric acid is sometimes used for recurrent BV that does not respond to conventional antibiotics. A retrospective study of 52 women with recurrent BV (averaging more than four episodes per year) who used 600 mg boric acid daily for 14 days found that about 89 percent achieved normal Nugent scores afterward, with large improvements in clinical markers and patient satisfaction.²⁰ Boric acid is not FDA-approved for this use, and it is toxic if swallowed, so it should only be used vaginally and never during pregnancy. Treat it as a last-resort option for stubborn cases, ideally under medical supervision.

Adding Probiotics to Antibiotic Treatment

Because BV involves a collapse of the healthy Lactobacillus-dominated vaginal microbiome, the idea of replenishing those bacteria during or after antibiotic treatment has a strong logical basis. The clinical evidence is mixed but leans positive for certain probiotic strains used alongside standard antibiotics.

In a randomized, double-blind trial, women who took oral Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 capsules during metronidazole treatment saw dramatically better outcomes: all probiotic-treated patients were free of BV at 30-day follow-up, compared with only 70 percent in the group receiving metronidazole plus placebo capsules.²¹ A larger double-blind study using probiotic capsules found that about 62 percent of the probiotic group had restored balanced vaginal microbiota, compared with 27 percent in the placebo group, and those gains held six weeks later.²²

A more targeted approach is under development: Lactin-V, a vaginal product containing a specific strain of Lactobacillus crispatus (a species that dominates healthy vaginal microbiomes). In a randomized trial, women who used Lactin-V after completing vaginal metronidazole had a 30 percent recurrence rate at 12 weeks, compared with 45 percent in the placebo group.²³ The benefit also held at 24 weeks. Lactin-V has not yet been approved for clinical use, but it represents one of the most promising recurrence-prevention strategies in the pipeline.

The catch with probiotics generally is that strain, dose, and delivery method all matter enormously. A random probiotic yogurt from the grocery store is unlikely to contain the specific strains studied in these trials, and even capsule products marketed for “vaginal health” may not have been tested for BV. If you want to try probiotics as an adjunct, look for products specifying the exact strains that have clinical trial data behind them.

BV Treatment During Pregnancy

BV during pregnancy has long been associated with a higher risk of preterm birth, and a meta-analysis of observational data supports the link between BV and preterm delivery.²⁴ This naturally raises the question of whether treating BV in pregnant women prevents early delivery. The answer, unfortunately, is that it generally does not.

A large randomized trial found that treating asymptomatic BV with metronidazole during pregnancy did not reduce preterm delivery at all: about 12 percent of women delivered early in both the treatment and placebo groups.²⁵ An individual-participant-data meta-analysis that pooled multiple trials reached a similar conclusion: neither metronidazole nor clindamycin significantly reduced preterm birth, and starting treatment earlier in pregnancy did not help either.²⁶ The U.S. Preventive Services Task Force has recommended against routine screening and treatment of asymptomatic BV in pregnant women to prevent preterm birth.²⁷

If you are pregnant and have symptomatic BV, though, treatment is still standard practice. Metronidazole and clindamycin are both considered acceptable during pregnancy for symptomatic relief. The evidence simply says that treating BV in the hope of preventing preterm birth does not work as a standalone strategy.

When BV Has No Symptoms

Some women with BV have no noticeable discharge, odor, or discomfort and only discover the condition during a routine exam or test. The question of whether to treat asymptomatic BV is genuinely debated. One study found that treating asymptomatic BV reduced subsequent chlamydia infections over six months, and some experts point out that women who think they have no symptoms may simply not recognize the signs as abnormal.²⁸ But the limitations of the existing trials, combined with the risk of side effects and the high recurrence rate, mean that the general recommendation for non-pregnant women without symptoms leans toward watchful waiting rather than automatic treatment. If you are about to undergo a gynecologic procedure where BV could cause complications, treatment before the procedure is more clearly warranted.

Hormonal Contraception and Recurrence

One intriguing observational finding is that estrogen-containing contraceptives appear to roughly halve the risk of BV recurrence.²⁹ Estrogen promotes the growth of Lactobacillus bacteria in the vagina and thickens the vaginal lining, both of which make the environment less hospitable to BV-associated organisms. However, a pilot randomized trial that assigned women to take the combined oral contraceptive pill specifically to prevent BV recurrence did not find a significant benefit, and the strongest predictor of recurrence in that trial was, again, sex with the same pre-treatment partner.³⁰ The upshot: if you are already on or considering estrogen-containing contraception for other reasons, it may offer a modest protective bonus against BV recurrence, but it is not a strong enough effect to use as a treatment strategy on its own.

Emerging Approaches That Target the Biofilm

Because the biofilm is the root cause of treatment failure and recurrence, a new generation of therapies is being designed to dismantle it directly. The most advanced of these is PM-477, a genetically engineered enzyme called an endolysin that specifically targets Gardnerella bacteria. In lab studies, PM-477 eliminated all Gardnerella biofilms within 24 hours at very low concentrations, and it showed high resistance to the development of bacterial tolerance.³¹ Other enzyme-based approaches being investigated include DNase, lysozyme, and a Pseudomonas-derived elastase called LasA that breaks down the protein scaffold holding the biofilm together.³² A systematic review cataloguing biofilm-disrupting agents found significant biofilm reduction across multiple enzyme classes in preclinical studies.³³

None of these agents have been tested in full-scale human clinical trials yet, so they are not something you can ask for at a pharmacy. But they represent a fundamentally different approach: instead of killing bacteria with antibiotics that cannot penetrate the biofilm, you strip the biofilm away first, making the bacteria vulnerable again. If these pan out in clinical trials, they could be combined with existing antibiotics to finally break the treat-relapse cycle.

Vaginal Microbiome Transplantation

At the experimental frontier sits vaginal microbiome transplantation, or VMT, where vaginal fluid from a healthy donor with a Lactobacillus-dominated microbiome is transferred to a patient with recurrent BV. In the first published case series, five women with intractable, recurrent BV were treated. Four achieved full long-term remission lasting 5 to 21 months, with restoration of a Lactobacillus-dominated microbiome. One had incomplete remission. Three of the four successes required more than one transplant, and one required a donor change before responding.³⁴ No adverse effects were observed, but the study involved only five patients and had no control group.

Several early-stage studies have since supported the general safety and promise of VMT, but significant practical questions remain: how to screen donors for pathogens, what preparation protocol to use, how to standardize the transplant material, and how to ensure the transplanted bacteria actually take hold permanently.³⁵ VMT is not available outside of research settings, and it will likely be years before it becomes a routine clinical option. Still, for women who have exhausted every conventional approach and continue to suffer from recurrent BV, it is a line of research worth watching.

Getting the Diagnosis Right

One underappreciated reason BV medication sometimes seems to fail is that the diagnosis was wrong in the first place. BV shares symptoms with other vaginal infections, particularly trichomoniasis and yeast infections, and each requires different treatment. The traditional “syndromic” approach, where a clinician makes a diagnosis based on symptoms alone without testing, correctly identifies BV only about 40 percent of the time in some settings. Point-of-care testing, including pH measurement, amine (whiff) testing, and microscopy for clue cells, raises detection to about 83 percent.³⁶ If you have been treated for BV multiple times without success, it is worth asking whether the diagnosis has been confirmed by testing rather than assumed from symptoms.